CVS HEALTH Corp
Close on Oct 19, 2026
- Market cap
- $119.28B
- P/E (TTM)
- 24.6
- Dividend yield
- 2.87%
About Cvs Health
Retail-Drug Stores and Proprietary Stores, SIC 5912
CVS Health Corporation is a diversified healthcare solutions enterprise providing health insurance, pharmacy services, and medical care delivery. The company conducts business through four reportable segments: Health Care Benefits, Health Services, Pharmacy & Consumer Wellness, and Corporate/Other. Through its Aetna operations, CVS Health offers commercial, Medicare Advantage, Medicare Part D prescription drug, and Medicaid health plans, alongside dental, behavioral health, and supplemental coverage. Through its CVS Caremark operations, the organization administers pharmacy benefit management solutions, including plan design, formulary oversight, and specialty and mail-order dispensing. Its customers encompass individual health plan members, employer groups, labor unions, commercial health plans, government programs, healthcare providers, and patients receiving care directly.
The company operates approximately 9,000 retail locations and more than 1,000 walk-in and primary care medical clinics across the United States. Its commercial and government health benefit products operate nationwide across U.S. states and Washington, D.C., and serve select members internationally. Additionally, CVS Health manages a pharmacy network comprising approximately 63,000 retail pharmacies throughout the United States, Puerto Rico, Guam, and the U.S. Virgin Islands. The provided text does not state the company's headquarters location.
Summary of the business section of Cvs Health's latest annual report, written by StockData.
Company profile
Company
- Legal name
- CVS HEALTH Corp
- Founded
- 1963
- Headquarters
- Woonsocket, RI
- Address
- One Cvs Dr. 02895
- Phone
- (401) 765-1500
- Website
- cvshealth.com
- Employees
- 300,000, Dec 31, 2025
- Industry
- Retail-Drug Stores and Proprietary Stores
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, Boston, Massachusetts
Stock & identifiers
- Ticker
- CVS
- Exchange
- NYSE
- Shares outstanding
- 1.28B, Jul 29, 2026
- Public float
- $86.38B, Jun 30, 2025
- Filer category
- Large accelerated filer
- Stock splits
- 2-for-1, Jun 7, 2005; 2-for-1, Jun 16, 1998; 2-for-1, Mar 15, 1989; 2-for-1, May 3, 1983
- SEC CIK
- 64803
- CUSIP
- 126650100
- ISIN
- US1266501006
- LEI
- 549300EJG376EN5NQE29
- EIN
- 05-0494040
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| J. David Joyner | President, CEO and Chair, Director | 70,349 |
| James David Clark | SVP, Cont & Chief Acct Officer | 27,606 |
| Amy Compton-Phillips | EVP, Chief Medical Officer | 9,592 |
| Brian Newman | EVP, Chief Financial Officer | 3,038 |
| Tilak Mandadi | EVP, Chief Exp & Tech Officer | 10,133 |
| Prem S. Shah | EVP and Group President | 64,356 |
| Steven H. Nelson | EVP and President, Aetna | 2,924 |
| Samrat S. Khichi | EVP, CPO and General Counsel | 33,421 |
| Heidi B. Capozzi | EVP and Chief People Officer | 13,108 |
| Thomas F. Cowhey | EVP and CFO | 41,109 |
| Fernando Aguirre | Director | 11,181 |
| Larry Robbins | Director | 4,824,799 |
| C. David Brown Ii | Director | 129,316 |
| J. Scott Kirby | Director | 14,434 |
| Guy P. Sansone | Director | 15,106 |
| John E. Gallina | Director | 582 |
| Michael F. Mahoney | Director | 6,555 |
| Leslie V. Norwalk | Director | 7,376 |
| Anne A. Finucane | Director | 22,747 |
| Alecia A. Decoudreaux | Director | 2,970 |
| Douglas H. Shulman | Director | 5,929 |
| Jeffrey R. Balser | Director | 15,717 |
| Roger N. Farah | Director | 19,438 |
| Nancy Ann Deparle | Director | 34,169 |
| Mary L. Schapiro | Director | 11,844 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 JDavid Joyner | $21.21M | $50.48M | $10.42M | $137 | $148 |
| FY2024 JDavid Joyner | $17.81M | $4.81M | $9.78M | $74 | $129 |
| FY2024 Karen SLynch | $23.43M | -$15.06M | $9.78M | $74 | $129 |
| FY2023 Karen SLynch | $21.62M | $7.50M | $9.28M | $125 | $126 |
| FY2022 Karen SLynch | $21.32M | $23.77M | $12.16M | $143 | $124 |
| FY2022 PEO1 | $21.32M | $23.77M | $12.16M | $143 | $124 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“With a talented and diverse workforce of more than 300,000 colleagues, we uphold the highest standards of ethics and transparency while creating value and delivering on our promises.”
Corporate history
Events identified from SEC filings